Arenare L相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模式肿瘤非特异性ctDNA分析用于卵巢癌微小残留病灶检测和风险分层：MITO16a/MaNGO-OV2试验结果

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2026.106087

Paracchini, L; Velle, A; Di Gennaro, P; Mannarino, L; Ancona, L; Lorusso, D; Cecere, S C; Colombo, N; Beltrame, L; Fagotti, A; Tasca, G; Piemontese, M; Arenare, L; Califano, D; Galdiero, F; Zadro, R; Chiodini, P; Perrone, F; Biagioli, E; D'Incalci, M; Romualdi, C; Pignata, S; Marchini, S

发表日期：2026

文献求助收藏

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients

HOBOE III期试验十年更新结果，比较曲普瑞林联合他莫昔芬或来曲唑，或唑来膦酸联合来曲唑治疗绝经前激素受体阳性早期乳腺癌患者

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2024.104085

Gravina, A; Gargiulo, P; De Laurentiis, M; Arenare, L; De Placido, S; Orditura, M; Cinieri, S; Riccardi, F; Ribecco, A S; Putzu, C; Del Mastro, L; Rossi, E; Ciardiello, F; Di Rella, F; Nuzzo, F; Pacilio, C; Caputo, R; Cianniello, D; Forestieri, V; Giuliano, M; Arpino, G; Orlando, L; Mocerino, C; Schettino, C; Piccirillo, M C; Gallo, C; Perrone, F

免疫/内分泌

发表日期：2025

文献求助收藏

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib

HR-SC 是一个学术界开发的机器学习框架，用于对 HRD 阳性卵巢癌患者进行分类并预测其对奥拉帕尼的敏感性。

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2025.105060

Beltrame, L; Mannarino, L; Sergi, A; Velle, A; Treilleux, I; Pignata, S; Paracchini, L; Harter, P; Scambia, G; Perrone, F; González-Martin, A; Berger, R; Arenare, L; Hietanen, S; Califano, D; Derio, S; Van Gorp, T; Dalessandro, M L; Fujiwara, K; Provansal, M; Lorusso, D; Buderath, P; Masseroli, M; Ray-Coquard, I; Pujade-Lauraine, E; Romualdi, C; D'Incalci, M; Marchini, S

发表日期：2025

文献求助收藏

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

晚期子宫内膜癌同源重组修复状态：来自随机 II 期 MITOEND 3 试验的探索性生物标志物分析

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2025.105919

Bartoletti, M; Passarelli, A; Fagotti, A; Andreetta, C; Tamberi, S; Lorusso, D; Pisano, C; Califano, D; Spina, A; De Angelis, C; Greco, F; De Cecio, R; Scaglione, G L; Russo, D; Ghizzoni, V; Cinieri, S; Sisoudiya, S D; Sokol, E S; Arenare, L; Schettino, C; Perrone, F; Farolfi, A; Pignata, S

子宫内膜癌

发表日期：2025

文献求助收藏

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatinâ+âpaclitaxel/avelumab (MITO-END3 trial).

外周单核细胞髓系衍生抑制细胞与接受卡铂+紫杉醇/avelumab治疗的单中心子宫内膜癌患者的分子亚型的关联（MITO-END3试验）

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s00262-025-04021-3

D'Alterio C, Rea G, Napolitano M, Coppola E, Spina A, Russo D, Azzaro R, Mignogna C, Scognamiglio G, Califano D, Arenare L, Schettino C, Pisano C, Cecere S C, Di Napoli M, Passarelli A, Perrone F, Pignata S, Scala S

细胞生物学

发表日期：2025

文献求助收藏

Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials

主观症状报告不足及其预后价值：12项癌症临床试验的汇总分析

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2024.102941

Arenare, L; Di Liello, R; De Placido, P; Gridelli, C; Morabito, A; Pignata, S; Nuzzo, F; Avallone, A; Maiello, E; Gargiulo, P; Schettino, C; Gravina, A; Gallo, C; Chiodini, P; Di Maio, M; Perrone, F; Piccirillo, M C

发表日期：2024

文献求助收藏

Corrigendum to "Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials": [ESMO Open 9 (2024) 102941]

对“主观症状报告不足及其预后价值：12 项癌症临床试验的汇总分析”的更正：[ESMO Open 9 (2024) 102941]

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2024.103693

Arenare, L; Di Liello, R; De Placido, P; Gridelli, C; Morabito, A; Pignata, S; Nuzzo, F; Avallone, A; Maiello, E; Gargiulo, P; Schettino, C; Gravina, A; Gallo, C; Chiodini, P; Di Maio, M; Perrone, F; Piccirillo, M C

发表日期：2024

文献求助收藏

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

瑞戈非尼单药治疗RAS突变型晚期结直肠癌患者二线治疗（STREAM）：一项学术性、多中心、单臂、两阶段II期研究

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2022.100748

Cardone, C; De Stefano, A; Rosati, G; Cassata, A; Silvestro, L; Borrelli, M; Di Gennaro, E; Romano, C; Nappi, A; Zanaletti, N; Foschini, F; Casaretti, R; Tatangelo, F; Lastoria, S; Raddi, M; Bilancia, D; Granata, V; Setola, S; Petrillo, A; Vitagliano, C; Gargiulo, P; Arenare, L; Febbraro, A; Martinelli, E; Ciardiello, F; Delrio, P; Budillon, A; Piccirillo, M C; Avallone, A

发表日期：2023

文献求助收藏

Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients

对 PROFFIT 问卷进行验证性分析，以评估癌症患者的经济负担

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2023.102192

Arenare, L; Porta, C; Barberio, D; Terzolo, S; Zagonel, V; Pisconti, S; Del Mastro, L; Pinto, C; Bilancia, D; Cinieri, S; Rizzo, M; Migliaccio, G; Montesarchio, V; Del Campo, L; De Lorenzo, F; Iannelli, E; Traclò, F; Gitto, L; Vaccaro, M C; Frontini, L; Giannarelli, D; Bryce, J; Piccirillo, M C; Jommi, C; Efficace, F; Riva, S; Di Maio, M; Gallo, C; Perrone, F

发表日期：2023

文献求助收藏

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

MITO16A/MaNGO-OV2 试验中检测卵巢癌同源重组缺陷的替代学术方法

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2022.100585

Capoluongo, E D; Pellegrino, B; Arenare, L; Califano, D; Scambia, G; Beltrame, L; Serra, V; Scaglione, G L; Spina, A; Cecere, S C; De Cecio, R; Normanno, N; Colombo, N; Lorusso, D; Russo, D; Nardelli, C; D'Incalci, M; Llop-Guevara, A; Pisano, C; Baldassarre, G; Mezzanzanica, D; Artioli, G; Setaro, M; Tasca, G; Roma, C; Campanini, N; Cinieri, S; Sergi, A; Musolino, A; Perrone, F; Chiodini, P; Marchini, S; Pignata, S

发表日期：2022

文献求助收藏